Syra Health Announces Closing of $2.1 Million Public Offering

Rhea-AI Summary

Syra Health Corp. (NASDAQ: SYRA) has announced the closing of its previously announced public offering, raising approximately $2.1 million before deducting fees and expenses. The offering included 3,203,125 shares of Class A common stock, along with Series A and Series B warrants to purchase up to 3,203,125 shares each, at a combined price of $0.64 per share and accompanying warrants.

The warrants have an exercise price of $0.64 per share, with Series A expiring in 18 months and Series B in 5 years. If fully exercised, the warrants could potentially bring in an additional $4.1 million. Syra Health plans to use the net proceeds for application development, sales and marketing, research and development, and general corporate purposes.

Positive

• Raised $2.1 million in gross proceeds from the public offering
• Potential for additional $4.1 million if all warrants are exercised
• Funds to be used for application development, sales, marketing, and R&D

Negative

• Significant dilution of existing shareholders due to the large number of new shares and warrants issued
• Low offering price of $0.64 per share may indicate weak market perception
• No assurance that warrants will be exercised, potentially limiting additional capital

Insights

Financial Analyst

Syra Health's $2.1 million public offering, while providing immediate capital, comes at a potential cost. The low offering price of $0.64 per share suggests weak market confidence or financial distress. The inclusion of warrants, potentially diluting existing shareholders by up to 100% if fully exercised, is concerning. However, this could bring an additional $4.1 million in capital.

The company's intent to use proceeds for development, marketing and R&D indicates a focus on growth, but the need for "general corporate purposes" might signal cash flow issues. Investors should closely monitor Syra's ability to leverage this capital for sustainable growth and improved financial health.

Market Research Analyst

This offering reveals challenges in Syra Health's market position. The low share price and warrant structure suggest difficulty in attracting investment through traditional means. It's important to understand why - is it due to market conditions, company performance, or sector-specific issues?

The focus on application development and R&D indicates Syra is betting on innovation to drive growth. However, the healthcare tech sector is highly competitive. Investors should assess Syra's unique value proposition and market fit. The success of this strategy will depend on the company's ability to develop compelling solutions and effectively penetrate the market with its sales and marketing efforts.

CARMEL, Ind., Sept. 13, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company"), a healthcare technology company powering better health by providing meaningful solutions, today announced the closing of its previously announced public offering of an aggregate of 3,203,125 shares of its Class A common stock, Series A warrants to purchase up to 3,203,125 shares of Class A common stock and Series B warrants to purchase up to 3,203,125 shares of Class A common stock (all the warrants, collectively, the "Series Warrants"), at a combined public offering price of $0.64 per share and accompanying Series Warrants. The Series Warrants have an exercise price of $0.64 per share and are exercisable immediately upon issuance. The Series A warrants expire on the eighteen-month anniversary of the initial issuance date and the Series B warrants expire on the five-year anniversary of the initial issuance date.

Rodman & Renshaw LLC acted as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering were approximately $2.1 million before deducting the placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Series Warrants, if fully exercised on a cash basis, will be approximately $4.1 million. No assurance can be given that any of the Series Warrants will be exercised. The Company intends to use the net proceeds from this offering for application development, sales and marketing, research and development and for general corporate purposes, including working capital, operating expenses, and capital expenditures.

The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-281583), which was declared effective by the Securities and Exchange Commission (the "SEC") on September 11, 2024. The offering was made only by means of a prospectus forming part of the effective registration statement relating to the offering. A final prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus may be obtained on the SEC's website at http://www.sec.gov and may also be obtained by contacting Rodman & Renshaw LLC at 600 Lexington Avenue, 32nd Floor, New York, NY 10022, by telephone at (212) 540-4414, or by email at info@rodm.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

ABOUT SYRA HEALTH

Syra Health is a healthcare technology company powering better health in challenging areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology products. Syra Health's offerings are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government. For more information, please visit www.syrahealth.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements regarding the anticipated use of proceeds from the offering, the exercise of the Series Warrants prior to their expiration, the Company's operations and business strategy, and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, changes in circumstances and market and other conditions. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

For Investor or Media Inquiries:
Syra Health
IR/PR and Marketing Director
Christine Drury
317-385-9227
christined@syrahealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/syra-health-announces-closing-of-2-1-million-public-offering-302248040.html

SOURCE Syra Health

FAQ

How much did Syra Health (SYRA) raise in its recent public offering?

Syra Health (SYRA) raised approximately $2.1 million in gross proceeds from its recent public offering before deducting fees and expenses.

What was the offering price for Syra Health's (SYRA) public offering on September 13, 2024?

The combined public offering price was $0.64 per share of Class A common stock and accompanying Series Warrants.

How many shares and warrants did Syra Health (SYRA) issue in its September 2024 offering?

Syra Health (SYRA) issued 3,203,125 shares of Class A common stock, along with Series A and Series B warrants to purchase up to 3,203,125 shares each.

What is the exercise price and expiration of the warrants issued by Syra Health (SYRA) in September 2024?

The warrants have an exercise price of $0.64 per share. Series A warrants expire in 18 months, while Series B warrants expire in 5 years from the issuance date.